IP Library › Granted Patent US 11,661,437
Granted Patent B2
US 11,661,437 · App. 16/969,137 · Granted May 30, 2023

Steroid derivative regulators, method for preparing the same, and uses thereof

Inventors: Yidong Su (Jiangsu, CN); Xiaopo Chen (Jiangsu, CN); Jun Wang (Jiangsu, CN); Rudi Bao (Jiangsu, CN)
Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.; Shanghai Hansoh Biomedical Co., Ltd.
C07J43/003A61P25/08A61P25/24C07J7/009C07J41/005C07J41/0094C07J53/004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,661,437
App. No.
16/969,137
Granted
May 30, 2023
Kind
B2
Abstract

Steroid derivative regulators, a method for preparing the same, and uses thereof are described. Specifically, a compound as shown in formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and uses thereof as a regulator of GABA A receptor for treating depression, convulsion, Parkinson's disease, and nervous system diseases are described, wherein the substituents of the formula (I) are as defined in the description.

Claims (5)

1. A compound of:

, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, comprising the compound, the stereoisomer thereof, or the pharmaceutically acceptable salt thereof according to claim 1 , and one or more pharmaceutically acceptable carriers, diluents or excipients.

3. A method of agonizing GABA A receptor in a subject in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 2 to the subject.

4. The method according to claim 3 , wherein the subject has a CNS-related disease and the CNS-related disease is selected from the group consisting of sleep disorder, mood disorder, schizophrenia spectrum disorder, spasmodic disorder, memory disorder and/or cognitive disorder, dyskinesia, personality disorder, autism spectrum disorder, pain, traumatic brain injury, vascular disease, substance abuse disorder and/or withdrawal syndrome, and tinnitus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2020
From: SU, YIDONG; CHEN, XIAOPO; WANG, JUN; BAO, RUDI
To: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.; SHANGHAI HANSOH BIOMEDICAL CO., LTD.
Reel/Frame 053508/0711 →
Priority Claims (4)
CN 201810141153.6 · Feb 11, 2018 · national
CN 201810180543.4 · Mar 5, 2018 · national
CN 201810491114.9 · May 21, 2018 · national
CN 201811407557.1 · Nov 23, 2018 · national
Continuity (1)
Related Publication 20220017565A1 · Jan 20, 2022
Cited By (2)
US 12,275,742 US 12,630,560